Authors

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

Stephen Freedland, MD, highlighted data showing significant overall survival benefits in the EMBARK trial and discussed the continued role of monotherapy in preserving quality of life for select patients.

ADA 2026: Survodutide Cuts Visceral Fat and Normalizes Liver Fat in MASLD. Here's What the Data Mean for Metabolic Risk

New SYNCHRONIZE data signal broad metabolic and hepatic benefits.

Preventing Adverse Drug Events: A Call to Action for Pharmacists

National Adverse Drug Event Awareness Day was established to promote awareness, drive policy changes, and encourage health care professionals and patients to prioritize medication safety.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

Dordaviprone: Safety, Efficacy, and Implications for Pharmacy Practice

New clinical findings highlight promising strategies for treating aggressive central nervous malignancies.

AI at the Counter: How Artificial Intelligence Is Shaping the Future of Pharmacy Practice

AI transforms pharmacy practice by streamlining workflows and enhancing patient care, while pharmacists adapt to new roles and challenges in health care.

Risks and Impacts of Cannabis Use During Pregnancy: A Growing Concern for Neonatal Health

Cannabis use during pregnancy may harm fetal development and long-term health.

Caffeine vs Guarana: Can AI Predict Which Stimulant Packs the Bigger Punch?

AI-driven analysis reveals guarana offers more sustained cognitive stimulation than caffeine, due to additional bioactive compounds and slower caffeine release kinetics.

Op-Ed: Prescribing Cascade Is Avoidable—If We Empower Pharmacists to Intervene

Pharmacy Fellowship Survival Guide: Work-Life Balance, Wellness, and Time Management Strategies

How to thrive professionally and personally during pharmacy fellowship

Reimagining Established Drugs Medicines Could Lead to Potential New Applications

The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.

Flushing the Old Away: Transitioning From Heparin to Saline for Implanted Port Maintenance

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

Half of Pharmacy Technicians Feel Fulfilled in Their Current Role

The Connecticut Society of Health-System Pharmacists Technician Committee survey explores the perception of career growth opportunities and challenges.

Pharmacy Logistics, Emerging Safety and Efficacy Data, and Future Directions for Menin Inhibitors in Acute Leukemias

Targeted menin inhibitors offer new hope for patients with difficult-to-treat acute leukemias.

Exploring the Antidepressant Potential of GLP-1 Receptor Agonists

GLP-1 receptor agonists show promise in alleviating depressive symptoms in patients with type 2 diabetes, offering a potential dual benefit in treatment.

Approval Pending: How to Plan for PDUFA Decisions

Tracking PDUFA decisions and early planning can lead to safe, rapid access to new medications for patients.

USP's Matt Christian: Why Drug Shortages Are Becoming Longer—and Harder to Solve

In an interview with Pharmacy Times, Matt Christian, director of Supply Chain Insights at USP, discussed the factors driving long-term shortages, the growing role of geographic concentration, and what pharmacists should understand about supply chain resilience.

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Dogs share a number of cancers with humans, including melanoma, non-Hodgkin lymphoma, leukemia, and osteosarcoma.

Exploring the Vascular Benefits of Semaglutide in Peripheral Artery Disease

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Rethinking Long-Term MS Therapy: De-Escalation, Biomarkers, and the Future of Care

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Jacci Bainbridge, PharmD, FCCP, Professor Vice Chair for Research and Scholarship, Neurology Pharmacy, presenting on current evidence surrounding discontinuation and de-escalation of disease-modifying therapies in multiple sclerosis, discusses rethinking long-term MS therapy, de-escalation, biomarkers and the future of care for MS.

Finerenone Shows Promise in Heart Failure and Kidney Disease Management

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL

BV-R2 combination shows survival benefit across high-risk subgroups.

Targeting Aldosterone at Its Source: The Arrival of Baxdrostat for Resistant Hypertension

By targeting aldosterone synthesis directly, baxdrostat offers a novel mechanism for addressing resistant hypertension.

Community Pharmacists Can Advance Vaccination in Cancer Care

Pharmacists should leverage their accessibility to boost immunization rates among individuals undergoing cancer treatment.

Driving Clinical Pharmacy Development With Data-Driven Metrics and Insights

There are no clearly defined, widely accepted clinical pharmacist metrics.

An Overview of Vitamins and Supplements in Multiple Sclerosis

By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.

Beyond the Prescription: How Pharmacists Address Social Barriers to Diabetes Care

Disparities in education access and quality, income level, and race and ethnicity are SDoH that make a major impact on diabetes and its management in the US.

Subcutaneous Pembrolizumab Matches IV in Lung Cancer Trial

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Improve Skin Health Through Student Pharmacist Education

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.